Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482541 | 0.84 | KMT2A (0.50) | KMT2AMEN1HDAC1HDAC6EGFR | |
| SCHEMBL11210779 | 0.83 | KMT2A (0.56) | KMT2AMEN1HDAC1HDAC6EGFR | |
| SCHEMBL3362719 | 0.81 | KMT2A (0.55) | KMT2AMEN1HDAC1HDAC6EGFR | |
| SCHEMBL1003249 | 0.81 | ALDH1A1 (0.58) | KMT2AMEN1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL7533635 | 0.80 | ALDH1A1 (0.55) | KMT2AMEN1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL438243 | 0.79 | KMT2A (0.53) | KMT2AMEN1HDAC1HDAC6EGFR | |
| SCHEMBL17629660 | 0.79 | KMT2A (0.53) | KMT2AMEN1HDAC1HDAC6EGFR | |
| SCHEMBL2282162 | 0.79 | KMT2A (0.53) | KMT2AMEN1HDAC1HDAC6EGFR | |
| SCHEMBL4585832 | 0.79 | KMT2A (0.53) | KMT2AMEN1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL20033534 | 0.79 | KMT2A (0.53) | KMT2AMEN1HDAC1HDAC6EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002062811-A2 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | claimed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| CN-102850336-A | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102702182-A | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-102558140-A | Derivatives of 4-piperazin-1-1-yl-4-benzo [b] thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-07-11 | — | — | CN | disclosed |
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| CN-101258147-B | 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders | OTSUKA PHARMA CO LTD | 2012-03-21 | — | — | CN | disclosed |
| EP-2284169-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| CN-101258147-A | 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002062811-A2 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2000055179-A1 | NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | KMT2A 480/4885MEN1 2715/4885HDAC1 126/4885 |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | KMT2A 4615/4885MEN1 3835/4885HDAC1 3866/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | KMT2A 480/4885MEN1 2715/4885HDAC1 126/4885 |
| US-20020147331-A1 | Methods for synthesis of oligonucleotides | RNGTT, TYMP, PNP | KMT2A 3974/4885MEN1 2222/4885HDAC1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.